This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
CDK2 Monoclonal Antibody (2B6 + 8D4)
catalog :
MA5-13725
quantity :
500µL
price :
US 349.00
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
2B6 + 8D4
reactivity :
hamsters, human, mouse, rat
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section
citations: 34
Published Application/Species/DilutionReference
  • western blot; human; 1:500; fig 3
Shi Z, Shi F, Wang Y, Sheftel A, Nie G, Zhao Y, et al. Mitochondrial ferritin, a new target for inhibiting neuronal tumor cell proliferation. Cell Mol Life Sci. 2015;72:983-97 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:500
Alonso S, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuña M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol. 2004;164:193-203 pubmed
  • immunohistochemistry - paraffin section; human; 1:500; tbl 1
Sáez A, Sáez A, Artiga M, Pérez-Rosado A, Camacho F, Diez A, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol. 2004;164:613-22 pubmed
  • immunohistochemistry - paraffin section; human; 1:400; fig 3
Mikami T, Yoshida T, Shiraishi H, Tokuyama W, Motoori T, Okayasu I. Bottom-up cell proliferation with cyclin A and p27Kip1 expression in ulcerative colitis-associated dysplasia. Pathol Int. 2006;56:10-6 pubmed
  • western blot; human; 1 ug/ml; fig 2
Chimploy K, Díaz G, Li Q, Carter O, Dashwood W, Mathews C, et al. E2F4 and ribonucleotide reductase mediate S-phase arrest in colon cancer cells treated with chlorophyllin. Int J Cancer. 2009;125:2086-94 pubmed publisher
Gomez A, Jarabo Sarceda J, García-Asenjo J, Fernandez C, Hernandez S, Sanz J, et al. Relationship of immunohistochemical biomarker expression and lymph node involvement in patients undergoing surgical treatment of NSCLC with long-term follow-up. Tumour Biol. 2014;35:4551-9 pubmed publisher
Azrak S, Ginel-Picardo A, Drosten M, Barbacid M, Santos E. Reversible, interrelated mRNA and miRNA expression patterns in the transcriptome of Rasless fibroblasts: functional and mechanistic implications. BMC Genomics. 2013;14:731 pubmed publisher
Whittaker S, Walton M, Garrett M, Workman P. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 2004;64:262-72 pubmed
Cameron R, Liu C, Mixon A, Pihkala J, Rahn R, Cameron P. Myosin16b: The COOH-tail region directs localization to the nucleus and overexpression delays S-phase progression. Cell Motil Cytoskeleton. 2007;64:19-48 pubmed
Sze S, Wong K, Liu W, Ng T, Wong J, Cheung H, et al. Regulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a chinese medicinal formula, in vitro and in vivo. Integr Cancer Ther. 2011;10:58-69 pubmed publisher
Yeh C, Lu S, Chao C, Chao M. Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant. Biochem Biophys Res Commun. 2003;305:311-4 pubmed
Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat. 2005;90:5-14 pubmed
Lewis J, Thomas T, Klinge C, Gallo M, Thomas T. Regulation of cell cycle and cyclins by 16alpha-hydroxyestrone in MCF-7 breast cancer cells. J Mol Endocrinol. 2001;27:293-307 pubmed
Santaguida M, Nepveu A. Differential regulation of CDP/Cux p110 by cyclin A/Cdk2 and cyclin A/Cdk1. J Biol Chem. 2005;280:32712-21 pubmed
Weroha S, Li S, Tawfik O, Li J. Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats. Carcinogenesis. 2006;27:491-8 pubmed
Wesierska-Gadek J, Borza A, Komina O, Maurer M. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential. Acta Biochim Pol. 2009;56:495-501 pubmed
Lin W, Lai M, Yeh C. Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth. Oncol Rep. 2013;29:903-10 pubmed publisher
Komina O, Wesierska-Gadek J. Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells. Biochem Pharmacol. 2008;76:1554-62 pubmed publisher
Wesierska-Gadek J, Borza A, Walzi E, Krystof V, Maurer M, Komina O, et al. Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment. J Cell Biochem. 2009;106:937-55 pubmed publisher
Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol. 2005;36:828-37 pubmed
Hudson T, Hartle D, Hursting S, Nunez N, Wang T, Young H, et al. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res. 2007;67:8396-405 pubmed
He G, Kuang J, Koomen J, Kobayashi R, Khokhar A, Siddik Z. Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents. Br J Cancer. 2013;109:2378-88 pubmed publisher
Rogalińska M, Błoński J, Komina O, Góralski P, Zołnierczyk J, Piekarski H, et al. R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. J Cell Biochem. 2010;109:217-35 pubmed publisher
Zhang Y, Xu P, Park K, Choi Y, Moore D, Wang L. Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology. 2008;48:289-98 pubmed publisher
Sandal T, Stapnes C, Kleivdal H, Hedin L, Døskeland S. A novel, extraneuronal role for cyclin-dependent protein kinase 5 (CDK5): modulation of cAMP-induced apoptosis in rat leukemia cells. J Biol Chem. 2002;277:20783-93 pubmed
Garcia J, Camacho F, Morente M, Fraga M, Montalban C, Alvaro T, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003;101:681-9 pubmed
Kutz H, Reisbach G, Schultheiss U, Kieser A. The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus. Virology. 2008;371:246-56 pubmed
Jirawatnotai S, Aziyu A, Osmundson E, Moons D, Zou X, Kineman R, et al. Cdk4 is indispensable for postnatal proliferation of the anterior pituitary. J Biol Chem. 2004;279:51100-6 pubmed
Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle. 2007;6:1102-14 pubmed
Sansregret L, Goulet B, Harada R, Wilson B, Leduy L, Bertoglio J, et al. The p110 isoform of the CDP/Cux transcription factor accelerates entry into S phase. Mol Cell Biol. 2006;26:2441-55 pubmed
Lai M, Chen T, Pang S, Yeh C. Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells. Urol Oncol. 2012;30:871-8 pubmed publisher
Santos C, Rodriguez-Pinilla M, Vega F, Rodriguez-Peralto J, Blanco S, Sevilla A, et al. VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. Mol Cancer Res. 2006;4:177-85 pubmed
Raynaud F, Whittaker S, Fischer P, McClue S, Walton M, Barrie S, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res. 2005;11:4875-87 pubmed
Wesierska-Gadek J, Gritsch D, Zulehner N, Komina O, Maurer M. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells. J Cell Biochem. 2011;112:1103-17 pubmed publisher
product information
Product Type :
Antibody
Product Name :
CDK2 Monoclonal Antibody (2B6 + 8D4)
Catalog # :
MA5-13725
Quantity :
500µL
Price :
US 349.00
Clonality :
Monoclonal
Purity :
protein A
Host :
Mouse
Reactivity :
Human, Mouse, Non-human primate, Rat
Applications :
Immunocytochemistry: 1:50-1:100, Immunofluorescence: 1:50-1:100, Immunohistochemistry (Paraffin): 1:20, Immunoprecipitation: 2 µg/ml, Western Blot: 1-2 µg/ml
Species :
Human, Mouse, Non-human primate, Rat
Clone :
2B6 + 8D4
Storage :
4° C
Description :
p33cdk2 associates with cyclin A in human cells. Kinase activity associated with cyclin A-cdc2 is found only in G2-phase. Cdk2 also complexes with cyclins E, D1, and D3. Cyclin E-cdk2 kinase is active in the G1- and S-phases of the cell cycle and is important (as does cyclin A-cdk2) for the progression from G1-to S-phase. The levels of cyclin A-cdk2 is maximal at the G1/S transition and both cdk2 and cyclin A are found associated with DNA in the initiation complex during replication. Rb protein acts as substrate for cdk2-cyclin E and/or cdk2-cyclin A in vivo. Cdk2 is activated and specifically localized to the nucleus during late G1-, S-, and G2-phase.
Immunogen :
Human recombinant cdk2 protein
Format :
Liquid
Applications w/Dilutions :
Immunocytochemistry: 1:50-1:100, Immunofluorescence: 1:50-1:100, Immunohistochemistry (Paraffin): 1:20, Immunoprecipitation: 2 µg/ml, Western Blot: 1-2 µg/ml
Aliases :
cdc2-related protein kinase, cell devision kinase 2, cell division protein kinase 2, p33 protein kinase
PubMed References :
11719282, 11909854, 12393683, 12745075, 14695333, 14729633, 14742266, 15456744, 15770521, 16000586, 16081423, 16084954, 16311245, 16398674, 16508018, 16547155, 17029291, 17457054, 17804756, 17967471, 18537191, 18761329, 19180585, 19585502, 19724778, 19911397, 20702488, 21308739, 21396835, 23292002, 24104967, 24156637, 24443268, 25213357
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
www.thermofisher.com
800-678-5599
headquarters: USA